Hospira’s Shortage Solution Draws FDA Warning Letter For Product Release
This article was originally published in The Gray Sheet
Executive Summary
FDA isn’t convinced by Hospira’s explanation for why it released non-GMP compliant product from its beleaguered Rocky Mount plant.